Crisis Management – is your company ready to manufacture needed drugs when disasters and pandemics happen?
No industry is immune from disasters or pandemics, and many are thrust into the middle or greatly impacted because of them. Earthquakes, fires, typhoons, tsunamis, hurricanes and pandemics happen, and Mother Nature does not discriminate on timing or location and often does not give much warning.
A Crisis Management Plan is an integral part of a corporate business plan for every industry. A crisis management plan is an established process a business can follow when a disruptive or emergency occurs. This is even more important for the pharmaceutical and biologic market, as they often need to produce and supply drugs to aid in the relief efforts and ensure the drug supply chain is not interrupted. However, manufacturing plants and supply chains can be greatly affected in a crisis.
This was a hot topic during the 2018 Excipient World event (formerly known as Excipient Fest), immediately following a turbulent summer/fall season that saw an earthquake and multiple hurricanes. Puerto Rico was especially hard hit from several hurricanes, impacting many pharmaceutical and biologic companies with manufacturing plants in the devastated area.
IPQ covered crisis management and emergency preparedness education presented at 2018 Excipient World and produced a four-part report on education sessions and discussions that made a significant contribution to understanding the global challenges industry and regulators were facing and what can be done to address them. This report is still highly relevant today to manufacturers facing similar issues due to the COVID-19 pandemic. The report includes:
- Significant investments that Biogen and Baxter are making in data collection, mapping, analysis, and communication in the context of these global challenges, and the multiple benefits the companies are reporting in supply chain resiliency and security as well as planning and employee safety.
- Regulator engagement in managing disasters. Provided are insights from FDA Emergency Operations Director Andrei Nabakowksi on the agency’s substantive response to Hurricane Maria and other crises
- A broader view of climatic, demographic, economic and political mega-trends and the planning that is called for from pharma and other global industries to prepare for the significant disruptions and risks they entail, based on insights from internationally recognized author and analyst Dante Disparte.
- Review of an expert panel discussion from Excipient World on the impact of a disaster like Hurricane Maria at the individual, company and government levels, and the lessons to be learned.
Access the complimentary IPQ report on crisis management .
IPQ is offering this issue complimentary as a public service due to its relevance to the pharmaceutical and biologics industry and regulators in addressing the COVID-19 crisis.
photo credit: AP – Ninian Reid